OCS letter to industry
This article was originally published in The Gray Sheet
Center for Devices and Radiological Health's office of compliance and surveillance sends letter to roughly 20,000 device manufacturers on Jan. 21 to clarify and solicit industry input on OCS initiatives. FDA says that it has advised field offices that FDA-483 citations "regarding the need for new 510(k)s or premarket approval application supplements because of changes to the device should not be made unless approved by CDRH." In addition, revision of the 510(k) regulations to require manufacturers to provide current information on device manufacturing and sterilizing locations "is under consideration," the letter says. The letter also explains OCS' "reference list," discusses fiscal year 1992 enforcement statistics, and provides updates on development of a revised good manufacturing practices regulation and enforcement of germicide manufacturers. Future letters may cover topics such as compliance policy guides under development and bioresearch monitoring....
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.
An interim final rule posted by the CMS this week widens further a series of telehealth exemptions and lab specimen collection payment provisions it has previously issued to help providers during the COVID-19 pandemic.